Clinical trial
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
NCT00132314 · US Department of Veterans Affairs, U.S. Fed · Completed
Key facts
| NCT number | NCT00132314 |
|---|---|
| Title | Long-Acting Injectable Risperidone in the Treatment of Schizophrenia |
| Official title | CSP #555 - Long-Acting Injectable Risperidone in the Treatment of Schizophrenia |
| Lead sponsor | US Department of Veterans Affairs, U.S. Fed |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizoaffective Disorder, Schizophrenia |
| Intervention type | Drug |
| Interventions | IM risperidone, oral antipsychotic medication |
| Enrollment | 382 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Aug 19, 2005 |
| Last update posted | Dec 20, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: